Dostarlimab: a promising new PD-1 inhibitor for cancer immunotherapy
Z Farzeen, RRM Khan, AR Chaudhry… - Journal of Oncology …, 2024 - journals.sagepub.com
Objective Dostarlimab, a humanized monoclonal PD-1 blocking antibody, is being tested as
a cancer therapy in this review. Specifically, it addresses mismatch repair failure in …
a cancer therapy in this review. Specifically, it addresses mismatch repair failure in …
[HTML][HTML] Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations
Highlights•A systematic review on cross-talk of dostarlimab with adaptive immunity and its
clinical trials, which are now being proven as breakthrough.•Recent developments in …
clinical trials, which are now being proven as breakthrough.•Recent developments in …
Dostarlimab: Review on success story and clinical trials
R Yadav, I Mathur, HR Haokip, AK Pandey… - Critical Reviews in …, 2024 - Elsevier
Abstract The PD-1/PD-L1 pathway plays a significant role in inhibiting, escaping from
immune response, and promoting self-tolerance of the tumour. Dostarlimab is a selective …
immune response, and promoting self-tolerance of the tumour. Dostarlimab is a selective …
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities
M Badenhorst, AD Windhorst, W Beaino - Frontiers in Medicine, 2024 - frontiersin.org
Immunotherapy targeted to immune checkpoint inhibitors, such as the program cell death
receptor (PD-1) and its ligand (PD-L1), has revolutionized cancer treatment. However, it is …
receptor (PD-1) and its ligand (PD-L1), has revolutionized cancer treatment. However, it is …
An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker
SS Biswas, S BabuV, A Chakraborty, A Chakraborty… - Heliyon, 2023 - cell.com
Cancer immunotherapy is a treatment that uses the body's own immune system to fight
against cancer. Malignant cells in the human body have the ability to mutate themselves in …
against cancer. Malignant cells in the human body have the ability to mutate themselves in …
The use of dostarlimab, a safe and efficient monotherapy in MSI-H rectal cancer patients, an alternative to surgery
Y Baz, M Rassam, E Rhayem, J Zouein, J Gharios… - …, 2023 - Taylor & Francis
Rectal cancer (RC) represents approximately 30% of all colorectal cancers (CRC).
Diagnosis and treatment of RC have witnessed important progress over the years [1] …
Diagnosis and treatment of RC have witnessed important progress over the years [1] …